Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT03829410 |
Title | Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation |
Recruitment | Completed |
Gender | both |
Phase | Phase Ib/II |
Variant Requirements | No |
Sponsors | Trovagene, Inc. |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
Mayo Clinic Cancer Center | Phoenix | Arizona | 85054 | United States | Details | |
CARTI Cancer Center | Little Rock | Arkansas | 72205 | United States | Details | |
USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | United States | Details | |
Mayo Clinic Florida | Jacksonville | Florida | 32224 | United States | Details | |
University of Kansas Medical Center Research Institute | Kansas City | Kansas | 66160 | United States | Details | |
Mayo Clinic Rochester | Rochester | Minnesota | 55905 | United States | Details | |
Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | United States | Details |